JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M008786200 on February 7, 2001

J. Biol. Chem., Vol. 276, Issue 18, 14842-14847, May 4, 2001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/18/14842    most recent
M008786200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nelson, J. M.
Right arrow Articles by Fry, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, J. M.
Right arrow Articles by Fry, D. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition*

James M. NelsonDagger and David W. Fry

From Pfizer Global Research and Development, Ann Arbor, Michigan 48105

The ErbB receptor family is implicated in the malignant transformation of several tumor types and is overexpressed frequently in breast, ovarian, and other tumors. The mechanism by which CI-1033 and gemcitabine, either singly or in combination, kill tumor cells was examined in two breast lines, MDA-MB-453 and BT474; both overexpress the ErbB-2 receptor. CI-1033, a potent inhibitor of the ErbB family of receptor tyrosine kinases, reduced levels of activated Akt in MDA-MB-453 cells. This effect alone, however, did not induce apoptosis in these cells. Gemcitabine treatment resulted in a moderate increase in the percentage of apoptotic cells that was accompanied by activation of p38 and MAPK (ERK1/2). CI-1033 given 24 h after gemcitabine produced a significant increase in the apoptotic fraction over treatment with either drug alone. During the combined treatment p38 remained activated, whereas Akt and activated MAPK were suppressed. Substitution of CI-1033 with the phosphatidylinositol 3-kinase inhibitor LY294002 and the MAPK/ERK kinase inhibitor PD 098059 in combination with gemcitabine produced the same results as the combination of CI-1033 and gemcitabine. p38 suppression by SB203580 prevented the enhanced cell kill by CI-1033. In contrast to MDA-MB-453, BT474 cells exhibited activated p38 under unstressed conditions as well as activated Akt and MAPK. Treatment of BT474 cells with CI-1033 inhibited both the phosphorylation of Akt and MAPK and resulted in a 47% apoptotic fraction. Gemcitabine did not cause apoptosis in the BT474 cells. These data indicate that suppression of Akt and MAPK in the presence of activated p38 results in cell death and a possible mechanism for the enhanced apoptosis produced by the combination of CI-1033 and gemcitabine in MDA-MB-453 cells. Furthermore, tumors that depend on ErbB receptor signaling for survival and exhibit activated p38 in the basal state may be susceptible to apoptosis by CI-1033 as a single agent.

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 734-622-7610; Fax: 734-622-7158; E-mail: James.Nelson@Pfizer.com.

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
S. R. Chinni, H. Yamamoto, Z. Dong, A. Sabbota, R. D. Bonfil, and M. L. Cher
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone
Mol. Cancer Res., March 1, 2008; 6(3): 446 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Lanza-Jacoby, R. Burd, F. E. Rosato Jr., K. McGuire, J. Little, N. Nougbilly, and S. Miller
Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6161 - 6169.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Y. Chun, F. Y. Feng, A. M. Scheurer, M. A. Davis, T. S. Lawrence, and M. K. Nyati
Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma
Cancer Res., January 15, 2006; 66(2): 981 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Nemunaitis, I. Eiseman, C. Cunningham, N. Senzer, A. Williams, P. F. Lenehan, S. C. Olson, P. Bycott, M. Schlicht, R. Zentgraff, et al.
Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3846 - 3853.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers
AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice
Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. L. Matheson, J. P. McNamee, T. Wang, M. A. Alaoui-Jamali, A. M. Tari, and B. J. Jean-Claude
The Combi-Targeting Concept: Dissection of the Binary Mechanism of Action of the Combi-Triazene SMA41 in Vitro and Antitumor Activity in Vivo
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1163 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. J. VanderWeele, R. Zhou, and C. M. Rudin
Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin
Mol. Cancer Ther., December 1, 2004; 3(12): 1605 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. F. Solca, A. Baum, E. Langkopf, G. Dahmann, K.-H. Heider, F. Himmelsbach, and J. C. A. van Meel
Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 502 - 509.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler
The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas
J. Clin. Oncol., May 15, 2004; 22(10): 1926 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
W. A. Swain, K. J. O'Byrne, and S. P. Faux
Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress
Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L859 - L865.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Bhattacharya, R. M. Ray, and L. R. Johnson
Prevention of TNF-{alpha}-induced apoptosis in polyamine-depleted IEC-6 cells is mediated through the activation of ERK1/2
Am J Physiol Gastrointest Liver Physiol, March 1, 2004; 286(3): G479 - G490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Nyati, D. Maheshwari, S. Hanasoge, A. Sreekumar, S. D. Rynkiewicz, A. M. Chinnaiyan, W. R. Leopold, S. P. Ethier, and T. S. Lawrence
Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo
Clin. Cancer Res., January 15, 2004; 10(2): 691 - 700.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. L. Janmaat and G. Giaccone
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, December 1, 2003; 8(6): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al.
Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission
Cancer Res., November 1, 2003; 63(21): 7221 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. S. Kruger and K. B. Reddy
Distinct Mechanisms Mediate the Initial and Sustained Phases of Cell Migration in Epidermal Growth Factor Receptor-Overexpressing Cells
Mol. Cancer Res., September 1, 2003; 1(11): 801 - 809.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, J. Arribas, S. Averbuch, and J. Baselga
ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells
Clin. Cancer Res., April 1, 2003; 9(4): 1274 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Nahta, G. N. Hortobagyi, and F. J. Esteva
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Oncologist, February 1, 2003; 8(1): 5 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Li and J. R. Bertino
Fas-mediated Signaling Enhances Sensitivity of Human Soft Tissue Sarcoma Cells to Anticancer Drugs by Activation of p38 Kinase
Mol. Cancer Ther., December 1, 2002; 1(14): 1343 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chakravarti, A. Chakladar, M. A. Delaney, D. E. Latham, and J. S. Loeffler
The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner
Cancer Res., August 1, 2002; 62(15): 4307 - 4315.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Wu, C. Wang, M. D'Amico, R. J. Lee, C. Albanese, R. G. Pestell, and S. Mani
Flavopiridol and Trastuzumab Synergistically Inhibit Proliferation of Breast Cancer Cells: Association with Selective Cooperative Inhibition of Cyclin D1-dependent Kinase and Akt Signaling Pathways
Mol. Cancer Ther., July 1, 2002; 1(9): 695 - 706.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chakravarti, J. S. Loeffler, and N. J. Dyson
Insulin-like Growth Factor Receptor I Mediates Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Primary Human Glioblastoma Cells through Continued Activation of Phosphoinositide 3-Kinase Signaling
Cancer Res., January 1, 2002; 62(1): 200 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. W. Rusnak, K. Lackey, K. Affleck, E. R. Wood, K. J. Alligood, N. Rhodes, B. R. Keith, D. M. Murray, W. B. Knight, R. J. Mullin, et al.
The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo
Mol. Cancer Ther., December 1, 2001; 1(2): 85 - 94.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.